Avalglucosidase alfa
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Glycogen Storage Disease Type II
Conditions
Glycogen Storage Disease Type II, Pompe's Disease
Trial Timeline
May 7, 2025 → May 2, 2028
NCT ID
NCT06666413About Avalglucosidase alfa
Avalglucosidase alfa is a approved stage product being developed by Sanofi for Glycogen Storage Disease Type II. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06666413. Target conditions include Glycogen Storage Disease Type II, Pompe's Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06666413 | Approved | Recruiting |
| NCT04910776 | Phase 3 | Active |
| NCT02032524 | Phase 2 | Completed |
Competing Products
20 competing products in Glycogen Storage Disease Type II